[The use of prodigiozan in the combined therapy of the sequelae of mild craniocerebral trauma].
Based on findings secured with the aid of instrumental and immunological techniques (electroencephalography, echoencephalography, roentgenoencephalography) a total of 57 patients with sequelae of mild craniocerebral injury were examined. Used in the study as an immunomodulating agent was prodigiosan. The drug was found to improve the bioelectrical activity of the brain, and to increase the amplitude of blood filling as evidenced by neurophysiological investigations. Moreover, prodigiosan makes for reduction of vegetovascular disorders and epileptic seizures, returning the level of neurospecific proteins to normal.
Mironenko
T V
TV
Panchenko
E N
EN
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D001921:Brain / Q000503:physiopathology; D003131:Combined Modality Therapy; D006259:Craniocerebral Trauma / Q000097:blood / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D018450:Disease Progression; D004750:Enteral Nutrition; D005260:Female; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000097:blood; D011354:Prodigiozan / Q000627:therapeutic use*; D012074:Remission Induction
D000276:Adjuvants, Immunologic; D009419:Nerve Tissue Proteins; D011354:Prodigiozan